Stopped The study was withdrawn as lesinurad was withdrawn from the market in Europe by the market authorization holder. Hence the commitment to do this PASS was removed by the European Medicines Agency.
Conditions
Gout
Hyperuricemia
Interventions
DRUG: Zurampic®
DRUG: Control group: xanthine oxidase inhibitor monotherapy